🔗 Share this article Patients Stopping Weight-Loss Medications Put On Pounds Four Times Faster Compared to Those on Conventional Diets Weight management often requires long-term strategies. Fresh analysis indicates that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise regimens. Research printed in a major medical journal shows that while overweight people can lose a large proportion of their total mass while on the medication, the mass is regained at an estimated rate of 0.8 kg per month after stopping. "People using these medications must be informed of the danger of rapid rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb. That rate of recovery implies a reversion to starting weight within about one and a half years. Comparing Therapies The study, which examined 37 of trials involving thousands of patients, compared the results of these new drugs with other pills. The team point out that individuals who lose weight through dieting generally see a slower creep back—perhaps 0.1 kg a month—after stopping. Explaining the Quick Rebound Nutrition scientists suggest the way of the injections is key to understanding the accelerated regain. The injections mimic a natural hormone called glucagon-like peptide-1, which controls hunger. "Artificially providing the hormone levels several times higher than the body's typical production might result in the system to produce less of its endogenous GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist. "Discontinuation of this medication results in appetite is unsuppressed, making binge eating a significant risk." A Lifelong Issue? The NHS recommend the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications. Many experts argue that, given the significant potential of relapse, the treatment might need to be long-term. This perspective is supported by pharmaceutical companies, who state that the findings "highlight the long-term nature of obesity," comparing it to managing conditions like hypertension. Patient Testimonies Users who have discontinued the medication explain a intense resurgence of cravings. "It felt as if a trigger that goes on and I was suddenly starving," described an individual. This challenge is exacerbated if patients have not developed sustainable lifestyle or habit changes during therapy. Significant Use Figures indicate that millions of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow. Adoption is greater among females than men. The middle-aged age group shows the greatest usage rates. Many obtain the drugs through private healthcare rather than the NHS. In conclusion, clinicians stress that while the jabs are effective agents for weight loss, they are not a permanent solution and lasting health benefits hinges on ongoing behavioural management.
Weight management often requires long-term strategies. Fresh analysis indicates that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise regimens. Research printed in a major medical journal shows that while overweight people can lose a large proportion of their total mass while on the medication, the mass is regained at an estimated rate of 0.8 kg per month after stopping. "People using these medications must be informed of the danger of rapid rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb. That rate of recovery implies a reversion to starting weight within about one and a half years. Comparing Therapies The study, which examined 37 of trials involving thousands of patients, compared the results of these new drugs with other pills. The team point out that individuals who lose weight through dieting generally see a slower creep back—perhaps 0.1 kg a month—after stopping. Explaining the Quick Rebound Nutrition scientists suggest the way of the injections is key to understanding the accelerated regain. The injections mimic a natural hormone called glucagon-like peptide-1, which controls hunger. "Artificially providing the hormone levels several times higher than the body's typical production might result in the system to produce less of its endogenous GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist. "Discontinuation of this medication results in appetite is unsuppressed, making binge eating a significant risk." A Lifelong Issue? The NHS recommend the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications. Many experts argue that, given the significant potential of relapse, the treatment might need to be long-term. This perspective is supported by pharmaceutical companies, who state that the findings "highlight the long-term nature of obesity," comparing it to managing conditions like hypertension. Patient Testimonies Users who have discontinued the medication explain a intense resurgence of cravings. "It felt as if a trigger that goes on and I was suddenly starving," described an individual. This challenge is exacerbated if patients have not developed sustainable lifestyle or habit changes during therapy. Significant Use Figures indicate that millions of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow. Adoption is greater among females than men. The middle-aged age group shows the greatest usage rates. Many obtain the drugs through private healthcare rather than the NHS. In conclusion, clinicians stress that while the jabs are effective agents for weight loss, they are not a permanent solution and lasting health benefits hinges on ongoing behavioural management.